IIVS | Direct Peptide Reactivity Activation Assay (DPRA, OECD 442C)
page-template-default,page,page-id-606,page-child,parent-pageid-540,ajax_fade,page_not_loaded,,qode_grid_1300,footer_responsive_adv,hide_top_bar_on_mobile_header,qode-content-sidebar-responsive,qode-child-theme-ver-,qode-theme-ver-11.0,qode-theme-bridge,wpb-js-composer js-comp-ver-,vc_responsive

Direct Peptide Reactivity Activation Assay (DPRA, OECD 442C)

The DPRA is an in chemico assay that identifies dermal sensitizers based on their reactivity with synthetic peptides containing either lysine or cysteine. The assay models the first key event, protein reactivity, in the skin sensitization AOP. Through collaboration with the method developers at Procter & Gamble, IIVS scientists received training, successfully demonstrated regulatory-required proficiency, and are offering the assay as a commercial service. IIVS is currently exploring the use of the OECD approved DPRA method (OECD 442C) in combination with other assays, including the KeratinoSensTM assay, to improve predictions.

Prepared samples to be loaded into the Separation Module.